Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

General practitioners will be able to prescribe the weight loss injection tirzepatide (Mounjaro) to “prioritised patient cohorts” from 23 June, NHS England has said. New interim commissioning guidance ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.